CNE100002RG2
CNE100002RG2
DASHENLIN PHARMACEUTICAL GROUP
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 21.37B EUR | 17.12B EUR | 20.25B EUR | 20.07B EUR |
Enterprise Value | 22.07B EUR | 17.01B EUR | 18.52B EUR | 19.06B EUR |
Valuation Multiples | ||||
Trailing P/E | 15.76x | 15.84x | 20.18x | 21.07x |
Forward P/E | 12.34x | -- | -- | -- |
Price to Sales | 0.76x | 0.8x | 0.97x | 0.96x |
Price to Book | 2.76x | 2.21x | 2.57x | 2.72x |
EV/Revenue | 0.79x | 0.79x | 0.88x | 0.91x |
EV/EBITDA | 8.88x | 7.75x | 9.04x | 14.57x |
Price to FCF (P/FCF) | 8.37x | 6.93x | 5.99x | 4.77x |
EV/FCF | 8.65x | 6.89x | 5.48x | 4.53x |
FCF Yield | 11.95% | 14.42% | 16.69% | 20.97% |